-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Extended pelvic nodule dissection (ePLND) is the gold standard for staging of prostate cancer (PCa) nodules
Recently, researchers from Italy published an article in "Eur Urol" describing the interim analysis results of a phase 2 prospective study (NCT04832958) of PSMA-RGS during RARP
The study was a phase 2 trial designed to enroll 100 patients with intermediate- or high-risk cN0cM0 PCa diagnosed on routine imaging with >5% risk of LNI
All patients underwent 68Ga-PSMA positron emission tomography (PET)/magnetic resonance imaging; 99mTc-PSMA-I&S was synthesized and injected intravenously the day before surgery, followed by single photon emission computed tomography/computed tomography
Four (33%), six (50%), and two (17%) patients in the study had intermediate-risk, high-risk, and locally advanced PCa, respectively
Diagnostic accuracy of individual patients
In conclusion, robotic-assisted PSMA-RGS is a safe and feasible method in primary staging with good specificity but poor sensitivity and may miss micrometastatic nodular disease
Original source:
Giorgio Gandaglia, Elio Mazzone, Armando Stabile et al.